|
|
| (19 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT[[Rifapentine]] |
| |authorTag={{KS}}
| |
| |genericName=rifapentine
| |
| |aOrAn=an
| |
| |drugClass=antimycobacterial drug
| |
| |indicationType=treatment
| |
| |indication=active [[pulmonary tuberculosis]] and [[latent tuberculosis]]
| |
| |adverseReactions=[[anemia]], [[lymphopenia]], [[neutropenia]], increased ALT, [[arthralgia]], [[conjunctivitis]], [[headache]], [[vomiting]], [[nausea]], [[diarrhea]], [[rash]], [[pruritus]], [[anorexia]] and [[lymphadenopathy]]
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| |
| | |
| * Content
| |
| | |
| <!--Adult Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
| |fdaLIADAdult===Indications==
| |
| | |
| '''Active Pulmonary Tuberculosis'''
| |
| | |
| * PRIFTIN® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active [[pulmonary tuberculosis]] ([[TB]]) caused by [[Mycobacterium tuberculosis]]. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible.
| |
| | |
| '''Limitations of Use'''
| |
| | |
| * Do not use PRIFTIN monotherapy in either the initial or the continuation phases of active antituberculous treatment.
| |
| | |
| * PRIFTIN should not be used once-weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms.
| |
| | |
| * PRIFTIN has not been studied as part of the initial phase treatment regimen in HIV- infected patients with active pulmonary tuberculosis.
| |
| | |
| '''Latent Tuberculosis Infection'''
| |
| | |
| * PRIFTIN is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by Mycobacterium tuberculosis in patients at high risk of progression to tuberculosis disease (including those in close contact with active tuberculosis patients, recent conversion to a positive tuberculin skin test, HIV-infected patients, or those with pulmonary fibrosis on radiograph).
| |
| | |
| '''Limitations of Use'''
| |
| | |
| * Active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection.
| |
| | |
| * PRIFTIN must always be used in combination with isoniazid as a 12-week once-weekly regimen for the treatment of latent tuberculosis infection.
| |
| | |
| * PRIFTIN in combination with isoniazid is not recommended for Individuals presumed to be exposed to rifamycin- or - isoniazid resistant M. tuberculosis.
| |
| | |
| ==Dosage==
| |
| | |
| '''Dosage in Active Pulmonary Tuberculosis'''
| |
| | |
| * PRIFTIN is only recommended for the treatment of active pulmonary tuberculosis caused by drug-susceptible organisms as part of regimens consisting of a 2 month initial phase followed by a 4 month continuation phase.
| |
| | |
| * PRIFTIN should not be used in the treatment of active pulmonary tuberculosis caused by rifampin-resistant strains.
| |
| | |
| * '''Initial phase (2 Months)''': PRIFTIN should be administered at a dose of 600 mg twice weekly for two months as directly observed therapy (DOT), with an interval of no less than 3 consecutive days (72 hours) between doses, in combination with other anti- tuberculosis drugs as part of an appropriate regimen which includes daily companion drugs such as isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA).
| |
| | |
| * '''Continuation phase (4 Months)''': Following the initial phase (2 months), continuation phase (4 months) treatment consists of PRIFTIN 600 mg once-weekly for 4 months in combination with isoniazid or another appropriate anti- tuberculosis agent for susceptible organisms administered as directly observed therapy.
| |
| | |
| '''Dosage in Latent Tuberculosis Infection'''
| |
| | |
| * PRIFTIN should be administered once-weekly in combination with isoniazid for 12 weeks as directly observed therapy.
| |
| | |
| * '''Adults and children 12 years and older''': The recommended dose of PRIFTIN should be determined based on weight of the patient up to a maximum of 900 mg once-weekly (see TABLE 1). The recommended dose of isoniazid is 15 mg/kg (rounded to the nearest 50 mg or 100mg) up to a maximum of 900 mg once-weekly for 12 weeks.
| |
| | |
| * '''Children 2–11 years''': The recommended dose of PRIFTIN should be determined based on weight of the patient up to a maximum of 900 mg once- weekly (see TABLE 1). The recommended dose of isoniazid is 25 mg/kg (rounded to the nearest 50 mg or 100mg) up to a maximum of 900 mg once-weekly for 12 weeks.
| |
| | |
| [[File:XXXXX.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
| | |
| ==DOSAGE FORMS AND STRENGTHS==
| |
| | |
| * PRIFTIN is supplied as 150 mg round normal convex dark-pink film-coated tablets debossed "Priftin" on top and "150" on the bottom.
| |
| |offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| |offLabelAdultNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| |fdaLIADPed=* There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| | |
| <!--Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| |offLabelPedNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| |contraindications='''Hypersensitivity'''
| |
| | |
| * PRIFTIN is contraindicated in patients with a history of [[hypersensitivity]] to rifamycins.
| |
| |warnings='''Hepatotoxicity'''
| |
| | |
| * Elevations of liver transaminases may occur in patients receiving PRIFTIN. Patients on PRIFTIN should be monitored for symptoms of liver injury.
| |
| | |
| * Patients with abnormal liver tests and/or liver disease or patients initiating treatment for active pulmonary tuberculosis should only be given PRIFTIN in cases of necessity and under strict medical supervision. In such patients, obtain serum transaminase levels prior to therapy and every 2–4 weeks while on therapy. Discontinue PRIFTIN if evidence of liver injury occurs.
| |
| | |
| '''Hypersensitivity and Related Reactions'''
| |
| | |
| * Hypersensitivity reactions may occur in patients receiving PRIFTIN. Signs and symptoms of these reactions may include hypotension, urticaria, angioedema, acute bronchospasm, conjunctivitis, thrombocytopenia, neutropenia or flu-like syndrome (weakness, fatigue, muscle pain, nausea, vomiting, headache, fever, chills, aches, rash, itching, sweats, dizziness, shortness of breath, chest pain, cough, syncope, palpitations). There have been reports of anaphylaxis.
| |
| | |
| * Monitor patients receiving PRIFTIN therapy for signs and/or symptoms of hypersensitivity reactions. If these symptoms occur, administer supportive measures and discontinue PRIFTIN.
| |
| | |
| '''Relapse in the Treatment of Active Pulmonary Tuberculosis'''
| |
| | |
| * PRIFTIN has not been evaluated as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary TB.
| |
| | |
| * Do not use PRIFTIN as a once-weekly continuation phase regimen in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin-resistant organisms.
| |
| | |
| * Higher relapse rates may occur in patients with cavitary pulmonary lesions and/or positive sputum cultures after the initial phase of active tuberculosis treatment and in patients with evidence of bilateral pulmonary disease. Monitor for signs and symptoms of TB relapse in these patients.
| |
| | |
| * Poor adherence to therapy is associated with high relapse rate. Emphasize the importance of compliance with therapy [see PATIENT COUNSELING INFORMATION (17)]
| |
| | |
| '''Drug Interactions'''
| |
| | |
| * Rifapentine is an inducer of CYP450 enzymes. Concomitant use of rifapentine with other drugs metabolized by these enzymes, such as protease inhibitors, certain reverse transcriptase inhibitors, and hormonal contraception may cause a significant decrease in plasma concentrations and loss of therapeutic effect.
| |
| | |
| '''Discoloration of Body Fluids'''
| |
| | |
| * PRIFTIN may produce a red-orange discoloration of body tissues and/or fluids (e.g., skin, teeth, tongue, urine, feces, saliva, sputum, tears, sweat, and cerebrospinal fluid). Contact lenses or dentures may become permanently stained.
| |
| | |
| '''Clostridium difficile-Associated Diarrhea'''
| |
| | |
| * Clostridium difficile-associated diarrhea (CDAD) has been reported with the use of nearly all systemic antibacterial agents, including PRIFTIN, with severity ranging from mild diarrhea to fatal colitis. Treatment with antibacterial agents can alter the normal flora of the colon and may permit overgrowth of C. difficile.
| |
| | |
| * C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur over two months after the administration of antibacterial agents.
| |
| | |
| * If CDAD is suspected or confirmed, discontinue antibacterial use not directed against C. difficile if possible. Institute appropriate measures such as fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated.
| |
| | |
| '''Porphyria'''
| |
| | |
| * Porphyria has been reported in patients receiving rifampin, attributed to induction of delta amino levulinic acid synthetase. Because PRIFTIN may have similar enzyme induction properties, avoid the use of PRIFTIN in patients with porphyria.
| |
| |alcohol=Alcohol-Rifapentin interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| }}
| |